238 related articles for article (PubMed ID: 18779052)
41. Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.
Hu Z; Kuritzkes DR
J Virol; 2014 Aug; 88(16):9268-76. PubMed ID: 24899199
[TBL] [Abstract][Full Text] [Related]
42. Acyclovir-resistant herpes simplex virus type 1 in intra-ocular fluid samples of herpetic uveitis patients.
van Velzen M; Missotten T; van Loenen FB; Meesters RJ; Luider TM; Baarsma GS; Osterhaus AD; Verjans GM
J Clin Virol; 2013 Jul; 57(3):215-21. PubMed ID: 23582986
[TBL] [Abstract][Full Text] [Related]
43. Genotypic and phenotypic characterization of acyclovir-resistant herpes simplex viruses isolated from haematopoietic stem cell transplant recipients.
Stránská R; van Loon AM; Polman M; Beersma MF; Bredius RG; Lankester AC; Meijer E; Schuurman R
Antivir Ther; 2004 Aug; 9(4):565-75. PubMed ID: 15456088
[TBL] [Abstract][Full Text] [Related]
44. Resistance of herpes simplex viruses to acyclovir: an update from a ten-year survey in France.
Frobert E; Burrel S; Ducastelle-Lepretre S; Billaud G; Ader F; Casalegno JS; Nave V; Boutolleau D; Michallet M; Lina B; Morfin F
Antiviral Res; 2014 Nov; 111():36-41. PubMed ID: 25218782
[TBL] [Abstract][Full Text] [Related]
45. Oxazole-Benzenesulfonamide Derivatives Inhibit HIV-1 Reverse Transcriptase Interaction with Cellular eEF1A and Reduce Viral Replication.
Rawle DJ; Li D; Wu Z; Wang L; Choong M; Lor M; Reid RC; Fairlie DP; Harris J; Tachedjian G; Poulsen SA; Harrich D
J Virol; 2019 Jun; 93(12):. PubMed ID: 30918071
[TBL] [Abstract][Full Text] [Related]
46. Antiretroviral therapy with protease inhibitors in human immunodeficiency virus type 1- and human herpesvirus 8-coinfected patients.
De Milito A; Catucci M; Venturi G; Romano L; Incandela L; Valensin PE; Zazzi M
J Med Virol; 1999 Feb; 57(2):140-4. PubMed ID: 9892398
[TBL] [Abstract][Full Text] [Related]
47. The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation.
McMahon MA; Siliciano JD; Lai J; Liu JO; Stivers JT; Siliciano RF; Kohli RM
J Biol Chem; 2008 Nov; 283(46):31289-93. PubMed ID: 18818198
[TBL] [Abstract][Full Text] [Related]
48. Novel dipeptide prodrugs of acyclovir for ocular herpes infections: Bioreversion, antiviral activity and transport across rabbit cornea.
Anand B; Nashed Y; Mitra A
Curr Eye Res; 2003; 26(3-4):151-63. PubMed ID: 12815543
[TBL] [Abstract][Full Text] [Related]
49. Characterization of herpes simplex viruses selected in culture for resistance to penciclovir or acyclovir.
Sarisky RT; Quail MR; Clark PE; Nguyen TT; Halsey WS; Wittrock RJ; O'Leary Bartus J; Van Horn MM; Sathe GM; Van Horn S; Kelly MD; Bacon TH; Leary JJ
J Virol; 2001 Feb; 75(4):1761-9. PubMed ID: 11160674
[TBL] [Abstract][Full Text] [Related]
50. Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring.
Moss JA; Malone AM; Smith TJ; Kennedy S; Kopin E; Nguyen C; Gilman J; Butkyavichene I; Vincent KL; Motamedi M; Friend DR; Clark MR; Baum MM
Antimicrob Agents Chemother; 2012 Feb; 56(2):875-82. PubMed ID: 22123689
[TBL] [Abstract][Full Text] [Related]
51. Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131.
Cihlar T; Ray AS; Boojamra CG; Zhang L; Hui H; Laflamme G; Vela JE; Grant D; Chen J; Myrick F; White KL; Gao Y; Lin KY; Douglas JL; Parkin NT; Carey A; Pakdaman R; Mackman RL
Antimicrob Agents Chemother; 2008 Feb; 52(2):655-65. PubMed ID: 18056282
[TBL] [Abstract][Full Text] [Related]
52. 9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine: a selective inhibitor of herpes group virus replication.
Field AK; Davies ME; DeWitt C; Perry HC; Liou R; Germershausen J; Karkas JD; Ashton WT; Johnston DB; Tolman RL
Proc Natl Acad Sci U S A; 1983 Jul; 80(13):4139-43. PubMed ID: 6306664
[TBL] [Abstract][Full Text] [Related]
53. [Antiviral activity of the organic germanium complex with aciclovir against herpes simplex virus (Herpesviridae: Alphaherpesvirinae: Simplexvirus: Human alphaherpesvirus 1/2) in the in vitro and in vivo systems].
Alimbarova LM; Ambrosov IV; Matelo SK; Barinsky IF
Vopr Virusol; 2021 Nov; 66(5):368-382. PubMed ID: 34738452
[TBL] [Abstract][Full Text] [Related]
54. Characterization of HIV-1 Resistance to Tenofovir Alafenamide In Vitro.
Margot NA; Johnson A; Miller MD; Callebaut C
Antimicrob Agents Chemother; 2015 Oct; 59(10):5917-24. PubMed ID: 26149983
[TBL] [Abstract][Full Text] [Related]
55. No selection of nucleoside reverse transcriptase inhibitor resistance associated mutations by acyclovir suppressive therapy in herpes simplex virus-2/HIV-1 dually infected persons.
LeGoff J; Tanton C; Delaugerre C; Weiss HA; Changalucha J; Ross DA; Mugeye K; Belec L; Hayes RJ; Watson-Jones D
AIDS; 2010 Oct; 24(16):2595-6. PubMed ID: 20940537
[No Abstract] [Full Text] [Related]
56. The helicase-primase inhibitor BAY 57-1293 reduces the Alzheimer's disease-related molecules induced by herpes simplex virus type 1.
Wozniak MA; Frost AL; Itzhaki RF
Antiviral Res; 2013 Sep; 99(3):401-4. PubMed ID: 23867133
[TBL] [Abstract][Full Text] [Related]
57. F18, a novel small-molecule nonnucleoside reverse transcriptase inhibitor, inhibits HIV-1 replication using distinct binding motifs as demonstrated by resistance selection and docking analysis.
Lu X; Liu L; Zhang X; Lau TC; Tsui SK; Kang Y; Zheng P; Zheng B; Liu G; Chen Z
Antimicrob Agents Chemother; 2012 Jan; 56(1):341-51. PubMed ID: 22037848
[TBL] [Abstract][Full Text] [Related]
58. Screening of herpes simplex virus type 1 isolates for acyclovir resistance using DiviTum® assay.
Sauerbrei A; Vödisch S; Bohn K; Schacke M; Gronowitz S
J Virol Methods; 2013 Mar; 188(1-2):70-2. PubMed ID: 23246510
[TBL] [Abstract][Full Text] [Related]
59. Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons.
Baeten JM; Lingappa J; Beck I; Frenkel LM; Pepper G; Celum C; Wald A; Fife KH; Were E; Mugo N; Sanchez J; Essex M; Makhema J; Kiarie J; Farquhar C; Corey L
J Infect Dis; 2011 Jan; 203(1):117-21. PubMed ID: 21148504
[TBL] [Abstract][Full Text] [Related]
60. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo.
Neyts J; Andrei G; De Clercq E
Antimicrob Agents Chemother; 1998 Feb; 42(2):216-22. PubMed ID: 9527762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
